GPSPJS
KYMR icon

General Pension Society PZU Joint Stock’s Kymera Therapeutics KYMR Stock Holding History

General Pension Society PZU Joint Stock’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,000
Closed -$294K – 19
2021
Q3 		$294K Sell
5,000
-3,000
-38% -$174K 0.09% 19
2021
Q2 		$388K Buy
+8,000
New +$347K 0.12% 19

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

General Pension Society PZU Joint Stock's KYMR Position: Q4 2021 in Review

General Pension Society PZU Joint Stock sold out of Kymera Therapeutics (KYMR) in Q4 2021, closing a stake of 5,000 shares — an estimated $294K sold.

General Pension Society PZU Joint Stock first reported a position in KYMR in Q2 2021 and held it in 2 quarters. The position peaked at $388K in Q2 2021. 128 funds tracked by Wall St. Rank hold KYMR as of Q4 2021.

  • General Pension Society PZU Joint Stock reported no remaining Kymera Therapeutics position as of Q4 2021 after selling out during the quarter.
  • General Pension Society PZU Joint Stock sold 5,000 Kymera Therapeutics shares in Q4 2021, an estimated $294K.
  • General Pension Society PZU Joint Stock first reported a position in Kymera Therapeutics in Q2 2021 and held it in 2 quarters.
  • General Pension Society PZU Joint Stock's Kymera Therapeutics position peaked at $388K in Q2 2021.
  • 128 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2021.

Based on General Pension Society PZU Joint Stock's 13F filing for Q4 2021, filed 13 Mar 2025.